These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 32790610)

  • 61. The Impact of 5α-Reductase Inhibitor Use for Male Pattern Hair Loss on Men's Health.
    Said MA; Mehta A
    Curr Urol Rep; 2018 Jun; 19(8):65. PubMed ID: 29909472
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Therapeutic hotline. Treatment of androgenic alopecia with finasteride may result in a high grade prostate cancer in patients: fact or fiction?
    Lynn R; Krunic A
    Dermatol Ther; 2010; 23(5):544-6. PubMed ID: 20868409
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Adverse event profiles of ifosfamide-induced encephalopathy analyzed using the Food and Drug Administration Adverse Event Reporting System and the Japanese Adverse Drug Event Report databases.
    Shimada K; Hasegawa S; Nakao S; Mukai R; Matsumoto K; Tanaka M; Uranishi H; Masuta M; Nishida S; Shimizu S; Hayashi Y; Suzuki A; Nakamura M
    Cancer Chemother Pharmacol; 2019 Nov; 84(5):1097-1105. PubMed ID: 31502115
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Clinical efficacy of oral administration of finasteride at a dose of 2.5 mg/day in women with female pattern hair loss.
    Won YY; Lew BL; Sim WY
    Dermatol Ther; 2018 Mar; 31(2):e12588. PubMed ID: 29464847
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Time Course of Incident Adverse Experiences Associated with Doxazosin, Finasteride and Combination Therapy in Men with Benign Prostatic Hyperplasia: The MTOPS Trial.
    Kaplan SA; Lee JY; Meehan AG; Kusek JW
    J Urol; 2016 Jun; 195(6):1825-9. PubMed ID: 26678956
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Potential cerebrovascular accident signal for risankizumab: A disproportionality analysis of the FDA Adverse Event Reporting System (FAERS).
    Woods RH
    Br J Clin Pharmacol; 2023 Aug; 89(8):2386-2395. PubMed ID: 36321844
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Sexual side effects of 5-α-reductase inhibitors finasteride and dutasteride: A comprehensive review.
    Fertig RM; Gamret AC; Darwin E; Gaudi S
    Dermatol Online J; 2017 Nov; 23(11):. PubMed ID: 29447628
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Safety profile of D-penicillamine: a comprehensive pharmacovigilance analysis by FDA adverse event reporting system.
    Kumar V; Singh AP; Wheeler N; Galindo CL; Kim JJ
    Expert Opin Drug Saf; 2021 Nov; 20(11):1443-1450. PubMed ID: 34259127
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Assessment of acute kidney injury related to small-molecule protein kinase inhibitors using the FDA adverse event reporting system.
    Fan Q; Ma J; Zhang B; Li Q; Liu F; Zhao B
    Cancer Chemother Pharmacol; 2020 Nov; 86(5):655-662. PubMed ID: 33001273
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Finasteride Topical Delivery Systems for Androgenetic Alopecia.
    Khan MZU; Khan SA; Ubaid M; Shah A; Kousar R; Murtaza G
    Curr Drug Deliv; 2018; 15(8):1100-1111. PubMed ID: 29366416
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Depression circumstantially related to the administration of finasteride for androgenetic alopecia.
    Altomare G; Capella GL
    J Dermatol; 2002 Oct; 29(10):665-9. PubMed ID: 12433001
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Psoriasis associated with ACE inhibitors: an analysis of the FAERS database.
    Ohyama K; Arai H; Sugiura M; Hori Y
    Pharmazie; 2020 Oct; 75(10):524-526. PubMed ID: 33305730
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Oral Finasteride Presents With Sexual-Unrelated Withdrawal in Long-Term Treated Androgenic Alopecia in Men.
    Perez-Mora N; Velasco C; Bermüdez F
    Skinmed; 2015; 13(3):179-83. PubMed ID: 26380503
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Persistent sexual side effects of finasteride for male pattern hair loss.
    Irwig MS; Kolukula S
    J Sex Med; 2011 Jun; 8(6):1747-53. PubMed ID: 21418145
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Statin-associated lower urinary tract symptoms: data mining of the public version of the FDA adverse event reporting system, FAERS.
    Fujimoto M; Hosomi K; Takada M
    Int J Clin Pharmacol Ther; 2014 Apr; 52(4):259-66. PubMed ID: 24472404
    [TBL] [Abstract][Full Text] [Related]  

  • 76. A Phase I, Open-Label, Sequential, Single-Dose Clinical Trial to Evaluate the Pharmacokinetic, Pharmacodynamic, and Safety of IVL3001, a Finasteride-Based Novel Long-Acting Injection for Androgenetic Alopecia.
    Kim H; Ryu C; Lee M; Lee KR; Kim J
    Adv Ther; 2024 Jul; 41(7):2936-2952. PubMed ID: 38833144
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Lack of Association between 5α-Reductase Inhibitors and Depression.
    Dyson TE; Cantrell MA; Lund BC
    J Urol; 2020 Oct; 204(4):793-798. PubMed ID: 32294395
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Evaluation of sexual function with an international index of erectile function in subjects taking finasteride for androgenetic alopecia.
    Tosti A; Pazzaglia M; Soli M; Rossi A; Rebora A; Atzori L; Barbareschi M; Benci M; Voudouris S; Vena GA
    Arch Dermatol; 2004 Jul; 140(7):857-8. PubMed ID: 15262698
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Efficacy and safety of finasteride therapy for androgenetic alopecia: a systematic review.
    Mella JM; Perret MC; Manzotti M; Catalano HN; Guyatt G
    Arch Dermatol; 2010 Oct; 146(10):1141-50. PubMed ID: 20956649
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System.
    Raschi E; Mazzarella A; Antonazzo IC; Bendinelli N; Forcesi E; Tuccori M; Moretti U; Poluzzi E; De Ponti F
    Target Oncol; 2019 Apr; 14(2):205-221. PubMed ID: 30927173
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.